e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Telix Pharmaceuticals Limited
< Previous
1
2
Next >
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
February 20, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
February 13, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Illuccix® Approved in the United Kingdom
February 12, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
January 30, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix Completes Acquisition of RLS (USA) Inc.
January 27, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Illuccix® Receives European Approval
January 16, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
January 13, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
January 12, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
December 30, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
December 29, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
December 19, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
November 18, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix ADSs Commence Trading on Nasdaq
November 13, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
November 13, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
November 03, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
October 30, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
October 23, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
October 22, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Files Form 20-F Registration Statement for Nasdaq ADS
October 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
October 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
October 03, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
September 22, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
September 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
CAH
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
September 10, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
September 03, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
August 27, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Announces Reorganisation to Deliver on Strategic Priorities
August 26, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
August 22, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
July 29, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.